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Diseases due to DNA damage repair machinery defects can resemble premature aging. In this issue of Cell
Metabolism, Scheibye-Knudsen et al. (2014) demonstrate that increasing NAD+ levels may reverse the inac-
tivation of Sirt1 and mitochondrial defects in Cockayne Syndrome B that stem from nuclear NAD+ depletion
by the DNA repair protein PARP.A number of diseases are due to loss of
function mutations in DNA repair proteins,
such as Cockayne Syndrome or xero-
derma pigmentosa, which are character-
ized by an increase in cancer and meta-
bolic abnormalities. Moreover, aspects
of these diseases resemble premature
aging, both in humans and mouse models
(Hoeijmakers, 2009). Recently, the Bohr
lab showed that one of these diseases,
xeroderma pigmentosa group A (XPA), re-
sulted in the chronic activation of the DNA
repair protein poly-ADP-ribose polymer-
ase (PARP) and a concomitant depletion
of NAD+ as PARP consumes it in order
to ADP-ribosylate proteins at sites of
DNA damage (Fang et al., 2014). This in
turn inactivated the NAD+-dependent de-
acetylase SIRT1 (Imai et al., 2000) and its
downstream target PGC-1a, resulting in
defective mitochondria with hyperpolar-
ized membranes and increased pro-
duction of reactive oxygen species.
Importantly, many of the metabolic phe-
notypes of XPA could be rescued byFigure 1. Pathway Leading to Mitochondrial Dysfunction in
Cockayne Syndrome B and Possible Therapeutic Interventions
The pathway by which Cockayne Syndrome B results in defective mitochon-
dria is traced in blue. The three interventions that ameliorate this problem,
PARP inhibition, NAD+ precursor supplementation, or ketogenic diets, are de-
picted in red. A second possible pathway emanating from ketogenic diets is
shown in gray.application of PARP inhibitors
or NAD+ precursors, such as
nicotinamidemononucleotide
(NMN) (Ramsey et al., 2008;
Yoshino et al., 2011) or nico-
tinamide riboside (NR) (Canto´
et al., 2012), which restored
NAD+ levels and SIRT1 activ-
ity in cells or animals.
In this issue of Cell Meta-
bolism (Scheibye-Knudsen
et al., 2014), the authors
describe phenotypes that
overlap with XPA in a mouse
model of Cockayne Syn-
drome group B (CSB), which
also leads to increased DNA
damage. In addition to the
metabolic studies discussed706 Cell Metabolism 20, November 4, 2014 ªbelow, the authors present novel
biochemical experiments that suggest
that a defect in CSB protein may activate
PARP by a novel mechanism yet to be
observed in other DNA repair defi-
ciencies. They demonstrate that CSB pro-
tein is recruited to sites of DNA damage
by poly-ADP-ribosylated proteins gener-
ated by PARP and then displaces PARP
to allow repair to proceed. Thus, in cells
missing CSB, active PARP will persist at
damaged sites, thereby exacerbating the
depletion of NAD+.
Interestingly, in addition to rescue by
NAD+ and PARP inhibitors, the authors
now show that a high-fat diet (HFD) can
also rescue the mitochondrial defects in
CSB tissues and cells resulting from the
hyperactivation of PARP (Figure 1). This
diet also signals the production of high
levels of ketones, such as b-hydroxybu-
terate. Ketones are made by the liver to
bridge a glucose deficit in the brain
when dietary carbohydrate is limiting; for
example, ketones rise substantially in2014 Elsevier Inc.mammals during fasting. Importantly, the
authors demonstrate that b-hydroxybu-
terate by itself can rescue CSB defects
in cells, suggesting that ketone produc-
tion may be key to the benefits provided
by the HFD to csb/ mice. This notion
has precedent as ketogenic diets have
previously been shown to protect against
oxidative stress in mice (Shimazu et al.,
2013).
Neurons in csb/ mice are particularly
sensitive, exhibiting the characteristic
mitochondrial defects and showing
extensive damage in the cerebellum and
the inner ear. PARP inhibitors or NAD+
precursors rescue these CSB pheno-
types, as does the HFD and b-hydroxybu-
terate. The authors suggest that ketones
may function by increasing the low
acetyl-CoA (Ac-CoA) levels they observe
in csb/ mice, resulting in an increase
in the activity of the histone acetyl trans-
ferase PCAF, which increases SIRT1
expression and possibly protein stability
(Figure 1). To wit, the authors imply thatthe levels of Ac-CoA are
depressed because csb/
mice feature a low NAD+/
NADH ratio, which shifts the
equilibrium of lactate dehy-
drogenase toward lactate
production, thus shunting py-
ruvate produced by glycolysis
away from mitochondrial
metabolism. The HFD fed
csb/ mice accordingly dis-
play a complete shift to fat
catabolism for energy, but
this is evidently not sufficient
for maintenance of normal
Ac-CoA levels. The authors
suggest that the provision of
ketones raises Ac-CoA levels
and activates PCAF, resulting
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b-hydroxybuterate is a well-known inhibi-
tor of class I and II histone deacetylases
(HDACs), it is likely that ketones also
induce many transcriptional changes via
HDAC inhibition, and these may result in
SIRT1 activation. The bottom line is that
all three interventions for CSB (PARP inhi-
bition, NAD+ precursor supplementation,
and HFD/ketones) require an active
SIRT1 to rescue themitochondrial defects
(Figure 1). This outcome may occur, in
part, because SIRT1 maintains normal
levels of uncoupling protein 2 (UCP2),
the lack of which results in tight coupling
of electron transport to ATP synthesis,
and hyperpolarization of the mitochon-
drial membrane.
Given the findings of Scheibye-Knud-
sen et al. (2014), what remains to be
done in order to better understand and
treat DNA damage repair deficiencies?
So far, the rescue of CSBbyNAD+ precur-
sors, PARP inhibitors, or ketones has
been demonstrated at the cellular level
or in specific tissues like the cerebellum.
It will be important to study whether
correction of the mitochondrial defects
extends to all affected tissues and amelio-
rates systemic phenotypes. Will supple-
mentation of csb/ mice with the NAD+
precursors, PARP inhibitors, or ketones
slow aging and extend life span? One
might predict a more complex effect of
PARP inhibitors, which will not only
restore NAD+ but also exacerbate theDNA repair defect in these animals. These
studies may also have translational impli-
cations for diseases due to DNA repair
defects, since all three treatments that
benefit csb/mice may be feasible in
humans.
More generally, a mechanism similar to
that represented in Figure 1 has also been
demonstrated in normal aging in a variety
of organisms (Mouchiroud et al., 2013),
suggesting that at least one aspect of ag-
ing can be attributed to the metabolic
fallout of DNA damage. By this logic, ag-
ing induces chronic DNA damage and
PARP activation, thereby leading to
NAD+ depletion, SIRT1 inactivation, and
mitochondrial dysfunction. Again, youth-
ful NAD+ levels can be restored in mice
by supplementing old animals with the
NAD+ precursors NMN (Ramsey et al.,
2008; Yoshino et al., 2011) or NR (Canto´
et al., 2012). Supplementation also leads
to health benefits in the aged mice,
including the restoration of mitochondrial
function to youthful levels in skeletal mus-
cle (Gomes et al., 2013). The decline
observed in normal aging attributable to
chronic DNA damage will, of course,
occur more rapidly in mice or humans
with XPA or CSB. It remains to be seen
whether NAD+ precursor supplementa-
tion improves mitochondrial function and
gives rise to overall health benefits in an
aging human population. If so, it will be
interesting to test whether NAD+ precur-
sor supplementation synergizes withCell Metabolism 20,small molecule activators of SIRT1 to
further increase the health span during
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